Cytek Biosciences (CTKB) Stock Price, News & Analysis

-0.15 (-2.58%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
477,762 shs
Average Volume
733,212 shs
Market Capitalization
$740.44 million
P/E Ratio
Dividend Yield
Price Target

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
59.0% Upside
$9.00 Price Target
Short Interest
8.35% of Float Sold Short
Dividend Strength
News Sentiment
0.47mentions of Cytek Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$266,100 Sold Last Quarter
Proj. Earnings Growth
From ($0.04) to $0.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

582nd out of 907 stocks

Analytical Instruments Industry

22nd out of 26 stocks

CTKB stock logo

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

CTKB Stock News Headlines

Fed launches fourth dollar overhaul
You've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???
Fed launches fourth dollar overhaul
You've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???
CTKB Mar 2024 5.000 put
Cytek Biosciences Reports Full Year 2023 Earnings
Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)
The Latest Analyst Ratings for Cytek Biosciences
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$193.01 million
Cash Flow
$0.02 per share
Book Value
$2.90 per share


Free Float
Market Cap
$740.44 million
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 60)
    President, CEO & Chairman of the Board
    Comp: $964.21k
  • Dr. Ming Yan Ph.D. (Age 61)
    CTO & Director
    Comp: $616.26k
  • Ms. Valerie T. Barnett J.D. (Age 48)
    Chief Legal Officer
    Comp: $535.98k
  • Mr. William D. McCombe (Age 66)
    Chief Financial Officer
  • Mr. Chris Williams (Age 55)
    Chief Operating Officer
  • Dr. Allen B. Poirson Ph.D. (Age 64)
    Senior Vice President of Business & Corporate Development
  • Dr. Philippe Busque Ph.D.
    Senior Vice President of Global Sales & Services
  • Mr. Patrik Sebastian Jeanmonod (Age 57)
    Head of Corporate Development Analytics
    Comp: $412.54k

CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price target for 2024?

5 Wall Street research analysts have issued 1 year price targets for Cytek Biosciences' shares. Their CTKB share price targets range from $7.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 59.0% from the stock's current price.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2024?

Cytek Biosciences' stock was trading at $9.12 at the beginning of 2024. Since then, CTKB shares have decreased by 37.9% and is now trading at $5.66.
View the best growth stocks for 2024 here

Are investors shorting Cytek Biosciences?

Cytek Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,950,000 shares, an increase of 16.9% from the March 15th total of 8,510,000 shares. Based on an average daily volume of 723,300 shares, the days-to-cover ratio is currently 13.8 days. Currently, 8.4% of the company's shares are short sold.
View Cytek Biosciences' Short Interest

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CTKB earnings forecast

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly earnings data on Wednesday, March, 13th. The company reported $0.04 earnings per share for the quarter. The company had revenue of $58.23 million for the quarter, compared to analyst estimates of $56.66 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.40% and a negative net margin of 6.29%.

What ETF holds Cytek Biosciences' stock?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 1,294 shares of CTKB stock, representing 0.33% of its portfolio.

What guidance has Cytek Biosciences issued on next quarter's earnings?

Cytek Biosciences updated its FY 2024 earnings guidance on Thursday, April, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $203.0 million-$213.0 million, compared to the consensus revenue estimate of $207.9 million.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 4/25/2024 by Staff

From Our Partners